NewLink Genetics Corp (NASDAQ:NLNK) has been assigned a consensus rating of “Buy” from the eight analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $22.40.
A number of brokerages have recently commented on NLNK. Zacks Investment Research cut NewLink Genetics from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. BidaskClub upgraded NewLink Genetics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Bank of America dropped their target price on NewLink Genetics from $22.00 to $18.00 and set a “buy” rating for the company in a report on Friday, March 2nd. Cantor Fitzgerald set a $26.00 target price on NewLink Genetics and gave the stock a “buy” rating in a report on Monday, January 8th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $21.00 target price (down previously from $25.00) on shares of NewLink Genetics in a report on Friday, March 2nd.
Institutional investors have recently made changes to their positions in the company. Redmile Group LLC boosted its holdings in NewLink Genetics by 67.9% during the 4th quarter. Redmile Group LLC now owns 2,096,490 shares of the biotechnology company’s stock valued at $17,003,000 after acquiring an additional 847,790 shares during the period. Vident Investment Advisory LLC purchased a new position in NewLink Genetics during the 4th quarter valued at $1,221,000. Millennium Management LLC boosted its holdings in NewLink Genetics by 56.6% during the 4th quarter. Millennium Management LLC now owns 2,347,359 shares of the biotechnology company’s stock valued at $19,037,000 after acquiring an additional 848,752 shares during the period. Teachers Advisors LLC boosted its holdings in NewLink Genetics by 79.8% during the 4th quarter. Teachers Advisors LLC now owns 133,355 shares of the biotechnology company’s stock valued at $1,082,000 after acquiring an additional 59,201 shares during the period. Finally, Raymond James & Associates purchased a new position in NewLink Genetics during the 4th quarter valued at $240,000. Hedge funds and other institutional investors own 65.05% of the company’s stock.
NewLink Genetics (NASDAQ:NLNK) last announced its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.32. The firm had revenue of $10.10 million during the quarter, compared to analysts’ expectations of $2.72 million. NewLink Genetics had a negative return on equity of 60.60% and a negative net margin of 250.60%. equities analysts predict that NewLink Genetics will post -2.35 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “NewLink Genetics Corp (NLNK) Given Consensus Recommendation of “Buy” by Analysts” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.wkrb13.com/2018/04/01/newlink-genetics-corp-nlnk-given-consensus-recommendation-of-buy-by-analysts.html.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.